证券代码：000403 证券简称：派林生物 公告编号：2025-036 派斯双林生物制药股份有限公司 第十届监事会第十一次会议（临时会议）决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第十届监事会第十一次会 议（临时会议）于2025年8月20日以通讯方式召开，会议由公司监事会主席郭麾先生 召集并主持。本次会议通知于2025年8月17日以通讯方式发出，会议应出席监事5人， 实际出席监事5人，会议程序符合《中华人民共和国公司法》和《派斯双林生物制药 股份有限公司章程》的有关规定。 与会监事经过认真讨论，审议了以下议案： 1、《2025 年半年度报告》 经审核，监事会认为董事会编制和审议公司 2025 年半年度报告的程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公司的实 际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内容详见《派斯双 林生物制药股份有限公司 2025 年半年度报告全文》《派斯双林生物制药股份有限公 司 2025 年半年度报 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-035 派斯双林生物制药股份有限公司 第十届董事会第十七次会议（临时会议）决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第十届董事会第十七次会 议（临时会议）于2025年8月20日以通讯方式召开，会议由公司董事长李昊先生召集 并主持。本次会议通知于2025年8月17日以通讯方式发出，会议应出席董事13人，实 际出席董事13人，会议程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事经过认真讨论，审议了以下议案： 1、《2025 年半年度报告》 公司 2025 年半年度报告全文及摘要按照中国证监会印发的《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》及深圳证券交易 所发布的《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》的要求编制。具体内容详见《派斯双林生物制药股份有限公司 2025 年半年度报 告全文》《派斯双林生物制药股份有限 ...

派林生物公告，2025年上半年营业收入9.86亿元，同比下降13.18%；净利润2.36亿元，同比下降 27.89%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 （文章来源：第一财经） ...

派斯双林生物制药股份有限公司 2025 年半年度报告 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 1 派斯双林生物制药股份有限公司 2025 年半年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司董事长李昊、财务总监王晔弘及会计机构负责人（会计主管人员）王 晔弘声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 派斯双林生物制药股份有限公司 2025 年半年度报告 2025 年 8 月 22 日 公司已在本报告第三节管理层讨论与分析及公司未来发展的展望部分，对 可能面临的风险进行了详细描述，请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 ...

证券日报网讯 8月20日晚间，天坛生物发布公告称，公司2025年第一次临时股东会审议通过了《关于变 更法定代表人的议案》《关于放弃收购派林生物商业机会的议案》。 （文章来源：证券日报） ...

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the change of legal representative and the decision to abandon the acquisition of a business opportunity with Pailin Biological [1][3][9] Group 1: Meeting Details - The meeting is scheduled for August 20, 2025, at 13:30 in Beijing [3] - Shareholders must register and present identification to receive meeting materials [1] - Latecomers will not have their votes counted unless approved by the meeting's working group [1][2] Group 2: Proposals - Proposal 1 involves changing the legal representative to Mr. Yang Huichuan [3] - Proposal 2 concerns the decision to abandon the acquisition of Pailin Biological, which is deemed to pose a competitive risk to the company [4][9] Group 3: Reasons for Abandoning Acquisition - The acquisition has a tight timeline, with a three-month window to finalize the transaction, which may not be feasible given the company's operational requirements [6][7] - The financial burden of a direct cash acquisition could strain the company's resources, as it would require significant capital [7] - The complexity of Pailin Biological's historical ownership and potential integration risks could adversely affect minority shareholders [8] Group 4: Impact of Abandoning Acquisition - The decision aligns with the company's strategy to maintain stable operations and protect investor interests [8][9] - The controlling shareholder, China Biological, will pursue the acquisition independently, ensuring compliance with previous commitments to avoid competition [9]

金融界消息 截至2025年8月11日收盘，派林生物（000403）报收于18.51元，下跌2.01%，换手率 2.27%，成交量21.34万手，成交金额3.95亿元。 资金流向方面，今日主力资金净流出1850.83万元，占比成交额4.69%。其中，超大单净流出1726.95万 元、占成交额4.37%，大单净流出123.88万元、占成交额0.31%，中单净流出流入3242.90万元、占成交 额8.21%，小单净流出1392.07万元、占成交额3.53%。 派林生物最新一期业绩显示，截至2025一季报，公司营业总收入3.75亿元、同比减少14.00%，归属净利 润8908.92万元，同比减少26.95%，扣非净利润7645.61万元，同比减少28.95%，流动比率4.191、速动比 率2.456、资产负债率12.94%。 天眼查商业履历信息显示，派斯双林生物制药股份有限公司，成立于1995年，位于太原市，是一家以从 事研究和试验发展为主的企业。企业注册资本73278.6558万人民币，实缴资本15375.2812万人民币。公 司法定代表人为李昊。 通过天眼查大数据分析，派斯双林生物制药股份有限公司共对外投资了8家 ...

Core Viewpoint - The acquisition of Plin Biological by Tiantan Biological has faced significant developments, with Tiantan opting to abandon the opportunity, allowing its controlling shareholder, China National Biological, to pursue the acquisition independently, raising questions about the potential formation of a "giant" in the blood products industry [1][2]. Group 1: Acquisition Details - Tiantan Biological's board approved the decision to forgo the acquisition of Plin Biological, which was previously announced as a major industry deal [2]. - China National Biological plans to acquire 21.03% of Plin Biological, with a transaction price based on 3.84 billion yuan plus annual simple interest [2]. - Tiantan Biological cited "high time constraints" as a reason for abandoning the acquisition, noting the scarcity and high demand for Plin Biological's assets [2][3]. Group 2: Challenges Faced - Tiantan Biological acknowledged facing "time window" and "funding pressure" challenges, as the acquisition process requires extensive regulatory approvals, which could delay the transaction [3]. - The potential acquisition price exceeding 3.84 billion yuan poses a significant financial burden on Tiantan Biological, which has a cash balance of 2.686 billion yuan as of the end of 2024 [3]. Group 3: Business Integration Risks - The complex historical background of Plin Biological, including multiple changes in control and organizational structure, presents integration risks that could affect minority shareholders [4]. - Tiantan Biological expressed concerns about the operational risks associated with directly acquiring Plin Biological, preferring that China National Biological handle the acquisition to facilitate better strategic alignment and resource integration [4]. Group 4: Industry Perspectives - Industry experts have mixed views on China National Biological's high-premium acquisition strategy, suggesting that it still resembles a "building block" approach rather than a cohesive industry leader [5]. - The increasing number of acquisitions raises integration challenges, including management unification, cultural differences, and balancing minority shareholder interests, which are critical for China National Biological's growth as a leading player in the industry [5].

血制品企业派林生物（000403.SZ）的控制权转让突生波澜。 8月5日，天坛生物宣布拟放弃此次收购机会，而不愿出手的原因主要是以下两点： 一是交易时间窗口只有3个月，短期内难以筹措如此大额的资金； 今年6月，中国生物技术股份有限公司（下称"中国生物"）计划收购派林生物控股股东共青城胜帮英豪 投资合伙企业（有限合伙）（下称"胜帮英豪"）所持有的全部股份（21.03%），交易金额不低于38.44 亿元。 截至2024年末，天坛生物的合并货币资金余额仅为26.86亿元，且需要留存生产经营所需资金，直接现 金收购存在较大的现金压力。 但中国生物旗下同时还控制着血制品企业天坛生物（600161.SH），这导致其与派林生物构成同业竞 争。 为了解决这一问题，中国生物计划将此次收购派林生物的机会让渡给天坛生物。 蹊跷的是，此举遭到天坛生物的拒绝。 派林生物内部管理层之间确实矛盾重重。 2023年10月，派林生物董事会改选，胜帮英豪提名了13名董事，将原董事长付绍兰"送出"董事会。 "如果选择由中国生物先进行收购，可以促使双方在战略规划、资源调配、文化融合等方面逐步达成共 识、充分磨合，并在此基础上提升运营效率，加快规模化 ...

Group 1: Pharmaceutical Regulations - Starting from August 1, all retail pharmacies in Foshan will implement a real-name registration system for the sale of 47 key controlled drugs, primarily for treating symptoms of Chikungunya fever [1] - The list of controlled drugs includes common medications such as Ibuprofen, Compound Cold Medicine, and Lianhua Qingwen capsules [1] Group 2: Clinical Trials and Drug Approvals - Kangning Jereh's innovative drug JSKN022, a PD-L1/αvβ6 dual-specific antibody drug conjugate, has received acceptance for clinical trial application from the National Medical Products Administration [3] - Yipin Hong's innovative drug APH03621 for endometriosis treatment has also received clinical trial registration acceptance from the National Medical Products Administration [5] - Lianhua Pharmaceutical's subsidiary has passed the consistency evaluation for the generic drug Lincomycin Hydrochloride Injection [4] Group 3: Financial Performance - China Resources Medical expects a profit decline of 20% to 25% for the first half of the year, with a significant drop of 55% to 60% when excluding one-time gains [6] - Zhenghai Bio reported a net profit of 46.49 million yuan for the first half of 2025, a decrease of 45.97% year-on-year, with revenue of 188 million yuan, down 5.14% [8] Group 4: Corporate Actions - Kexing Bio has spent 47.38 million yuan to repurchase 1.27 million shares, representing 0.63% of its total share capital [8] - WuXi AppTec has repurchased 6.51 million A-shares for a total of 497 million yuan [10] - Tian Tan Bio has decided to abandon the acquisition opportunity of Pailin Bio due to potential competition with its core business [9] Group 5: Industry Developments - Significant progress has been made in HIV vaccine research in China, with the completion of the first phase clinical trial for a replicating Tian Tan smallpox vaccine carrier HIV vaccine [11][13] - Sanofi announced the discontinuation of its PCSK9 inhibitor drug Alirocumab in China due to global supply issues and a strategic shift in its cardiovascular product line [12]